TABLE 3.
Effectiveness (by treatment line) of single‐capsule bismuth quadruple therapy in patients with antibiotic bacterial resistance
| Overall | First‐line | Second‐line | Third‐line | Fourth‐line | Fifth‐line | |
|---|---|---|---|---|---|---|
| Clarithromycin resistant | ||||||
| E | 26 | 2 | 7 | 6 | 7 | 4 |
| N | 30 | 2 | 7 | 9 | 7 | 5 |
| %E | 86.7 | 100 | 100 | 66.7 | 100 | 80 |
| 95% CI | (69–96) | (16–100) | (59–100) | (30–92) | (59–100) | (28–99) |
| Clarithromycin susceptible | ||||||
| E | 14 | 2 | 5 | 4 | 0 | 1 |
| N | 17 | 2 | 5 | 4 | 2 | 1 |
| %E | 82.4 | 100 | 100 | 100 | 0 | 100 |
| 95% CI | (56–96) | (16–100) | (48–100) | (40–100) | NA | (1.2–99) |
| Metronidazole resistant | ||||||
| E | 21 | 2 | 4 | 8 | 4 | 3 |
| N | 27 | 2 | 4 | 11 | 6 | 4 |
| %E | 77.8 | 100 | 100 | 72.7 | 66.6 | 75 |
| 95% CI | (58–91) | (16–100) | (40–100) | (39–94) | (22–95) | (19–99) |
| Metronidazole susceptible | ||||||
| E | 19 | 2 | 8 | 2 | 3 | 2 |
| N | 20 | 2 | 8 | 2 | 3 | 2 |
| %E | 95 | 100 | 100 | 100 | 100 | 100 |
| 95% CI | (75–99) | (16–100) | (63–100) | (16–100) | (29–100) | (16–100) |
| Dual resistant | ||||||
| E | 16 | 1 | 3 | 5 | 4 | 3 |
| N | 20 | 1 | 3 | 8 | 4 | 4 |
| %E | 80.0 | 100 | 100 | 62.5 | 100 | 75 |
| 95% CI | (56–94) | (1.2–99) | (29–100) | (24–91) | (40–100) | (19–99) |
| Dual susceptible | ||||||
| E | 24 | 3 | 9 | 5 | 3 | 2 |
| N | 27 | 3 | 9 | 5 | 5 | 2 |
| %E | 88.9 | 100 | 100 | 100 | 60 | 100 |
| 95% CI | (71–97) | (29–100) | (66–100) | (48–100) | (14–94) | (16–100) |
Abbreviations: % E, percentage eradication in the per‐protocol analysis; CI, confidence interval; E, number of patients eradicated; N, total number of patients treated; NA, not applicable.